ALXO Earnings & Financial Statements
ALX Oncology Holdings Inc.
$0.89
-$0.08(-8.67%)
32
Overall
60
Value
18
Tech
18
Quality
Market Cap
$123.72M
Volume
2.57M
52W Range
$1.05 - $2.66
Target Price
$4.60
ALXO earnings and financial statements: ALX Oncology Holdings Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ALXO Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$104.02M | -$142.47M | -$170.28M | -$127.44M | -$83.56M |
| EBITDA | -$99.11M | -$131.98M | -$159.63M | -$121.67M | -$82.73M |
| Net income | -$101.69M | -$134.85M | -$160.81M | -$123.48M | -$83.46M |
| EPS (diluted) | $-1.90 | $-2.58 | $-3.74 | $-3.03 | $-2.07 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $59.05M | $147.78M | $242.55M | $306.49M | $380.18M |
| Total liabilities | $33.06M | $34.16M | $52.84M | $43.02M | $17.13M |
| Shareholders’ equity | $25.98M | $113.62M | $189.71M | $263.46M | $363.05M |
| Cash and equivalents | $16.37M | $17.57M | $22.41M | $48.82M | $363.67M |
| Long-term debt | $4.53M | $9.47M | $9.64M | $9.39M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$84.14M | -$121.91M | -$130.36M | -$89.22M | -$68.10M |
| Capital expenditure | -$212.0K | -$447.0K | -$1.27M | -$1.43M | -$4.92M |
| Free cash flow | -$84.35M | -$122.36M | -$131.64M | -$90.65M | -$73.02M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ALXO | $0.89 | -8.7% | 2.57M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get ALX Oncology Holdings Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW